Nova Eye Medical (AU:EYE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nova Eye Medical Limited reported a surge in FY24 glaucoma segment sales, with a notable 37% increase to US$15.3 million and a remarkable 73% growth in the US market to US$11.4 million. This upswing marks the fourth consecutive half-year of revenue growth in the US, supported by the strategic recruitment of additional sales specialists and robust investments in marketing programs. A material improvement in the glaucoma segment’s operating results is anticipated for the second half of FY24, following this positive trend.
For further insights into AU:EYE stock, check out TipRanks’ Stock Analysis page.